Paper Details

  1. Home
  2. Paper Details

Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.

Author: GleasonShannon L, KhouryHanna Jean, ShenAnn Q, WilsonNicole M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Bosutinib is an oral tyrosine kinase inhibitor effective against all phases of resistant chronic myeloid leukemia (CML) that do not express the T315I or V299L ABL kinase domain mutations. While bosutinib has a unique toxicity profile, it is manageable and this review provides an overview of its pharmacodynamics, pharmacokinetic properties, treatment results in newly diagnosed and previously treated CML patients, and common side effects.
Paper Details　
Original Abstract of the Article :
Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile that is manageable. This paper provides an overview...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891288/

データ提供：米国国立医学図書館（NLM）

Bosutinib: A Potential Oasis in the Desert of Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

Chronic myelogenous leukemia (CML) is a complex and challenging hematological malignancy. This research explores the potential of bosutinib as a treatment for Philadelphia chromosome-positive (Ph+) CML. The authors provide an overview of bosutinib, including its pharmacodynamics, pharmacokinetics, and efficacy in treating both newly diagnosed and previously treated CML patients. They highlight bosutinib's unique toxicity profile and its effectiveness against various phases of resistant CML. The review underscores the significance of bosutinib as a valuable therapeutic option for patients with Ph+ CML.

Bosutinib: A Potential Oasis in the Desert of Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

Bosutinib has demonstrated significant efficacy in treating patients with Ph+ CML, both in the newly diagnosed and previously treated settings. Its ability to target various phases of resistant CML, including those with specific ABL kinase domain mutations, makes it a valuable tool for managing this challenging disease. The review emphasizes the importance of bosutinib as a potential treatment option for patients with Ph+ CML.

Bosutinib: A Potential Oasis in the Desert of Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

This research provides valuable insights into the potential of bosutinib as a therapeutic option for patients with Ph+ CML. The review highlights the significance of bosutinib in the treatment landscape, offering a potential oasis in the desert of CML. It underscores the importance of continued research and development of targeted therapies for this challenging malignancy.

Dr.Camel's Conclusion

This research provides a valuable overview of bosutinib as a potential treatment option for patients with Ph+ CML. The review highlights its unique characteristics and potential benefits in treating this challenging disease. It underscores the importance of continued research and development of targeted therapies for CML, offering a potential oasis in the desert of this complex hematological malignancy.

Date :
  1. Date Completed 2014-06-24
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24490020

DOI: Digital Object Identifier

PMC3891288

Related Literature

Article Analysis
・Side Effects of bosutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.